Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18477153 | 0.89 | MAPK1 (0.42) | LMNAHSP90AA1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL18477152 | 0.88 | HSP90AA1 (0.39) | LMNAHSP90AA1RAB9AKDM4EPOLB | |
| SCHEMBL18477164 | 0.88 | HSP90AA1 (0.34) | LMNAHSP90AA1KDM4ECTSLMEN1 | |
| SCHEMBL20414191 | 0.87 | SIRT6 (0.35) | LMNAHSP90AA1 | |
| SCHEMBL18477145 | 0.87 | SIRT6 (0.35) | HSP90AA1KDM4ESMN1; SMN2POLBCTSL | |
| SCHEMBL18477146 | 0.87 | APP (0.37) | HSP90AA1ALDH1A1RAB9AKDM4ECTSL | |
| SCHEMBL18477148 | 0.87 | HSP90AA1 (0.33) | LMNAHSP90AA1KDM4ESMN1; SMN2CTSL | |
| SCHEMBL20414192 | 0.87 | HSP90AA1 (0.33) | HSP90AA1KDM4ECTSLMEN1KMT2A | |
| SCHEMBL18477154 | 0.86 | PTAFR (0.40) | HSP90AA1 | |
| SCHEMBL18477156 | 0.86 | PHGDH (0.41) | LMNAALDH1A1KDM4ESMN1; SMN2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392397-B2 | Heterocyclic thiosemicarbazone derivatives and their therapeutical applications | NANTBIO, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180208603-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180208603-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC | 2018-07-26 | — | — | US | disclosed |
| WO-2017024315-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392397-B2 | Heterocyclic thiosemicarbazone derivatives and their therapeutical applications | TPMT, MKI67, TST | LMNA 4312/4885NPSR1 4469/4885HSP90AA1 158/4885 |
| US-20180208603-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | TPMT, MKI67, TST | LMNA 4312/4885NPSR1 4469/4885HSP90AA1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.